Stay updated on ADXS-NEO Personalized Tumor Antigens Clinical Trial

Sign up to get notified when there's something new on the ADXS-NEO Personalized Tumor Antigens Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the ADXS-NEO Personalized Tumor Antigens Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    No Change Detected
  4. Check
    3 days ago
    No Change Detected
  5. Check
    4 days ago
    No Change Detected
  6. Check
    5 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the Phase 1 clinical trial study of ADXS-NEO administered alone and in combination with pembrolizumab for participants with select advanced or metastatic solid tumors. This change reflects a potential advancement in personalized tumor antigen immunotherapy research within the medical and healthcare field.
    Difference
    0.1%
    Check dated 2024-06-06T14:44:45.000Z thumbnail image
  7. Check
    20 days ago
    Change Detected
    Summary
    The webpage has been updated to include detailed eligibility criteria for participation in the study, specifying health conditions and prior treatments required for inclusion. Previously, no information was provided about the participation criteria for collaborators and investigators.
    Difference
    64%
    Check dated 2024-05-22T21:26:22.000Z thumbnail image
  8. Check
    42 days ago
    Change Detected
    Difference
    0.6%
    Check dated 2024-04-30T22:21:57.000Z thumbnail image

Stay in the know with updates to ADXS-NEO Personalized Tumor Antigens Clinical Trial

Enter your email address, and we'll notify you when there's something new on the ADXS-NEO Personalized Tumor Antigens Clinical Trial page.